Displayed in English — localised translation pending
blog
Last updated: 2023-06-03

(大腸癌)Pertuzumab+Trastuzumab併用療法獲得批准

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
(大腸癌)Pertuzumab+Trastuzumab併用療法獲得批准

(大腸癌)Pertuzumab+Trastuzumab併用療法獲得批准

(大腸癌)Pertuzumab+Trastuzumab併用療法獲得批准

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

(大腸癌)Pertuzumab+Trastuzumab併用療法獲得批准

  • 2022年4月8日
  • 讀畢需時 1 分鐘

2022年3月28日,中外製藥株式會社發表了Pertuzumab+Trastuzumab併用療法獲得了厚生勞動省的批准,用於治療化療後症狀加重且無法進行切除的HER2陽性復發結直腸癌患者。

HER2陽性大腸癌是一種罕見的亞型,在大腸癌中有1~5%的患者屬於該類型,Pertuzumab及Trastuzumab都是屬於抗HER2抗體,併用時可廣泛阻斷HER信號系統,進而產生抗腫瘤作用。

本次批准是根據TRIUMPH第二期臨床試驗的結果,該試驗是向曾有化學療法經歷、無法進行切除的HER2陽性復發結直腸癌患者(N=30人)進行,主要評價項目客觀反應率在HER2陽性腫瘤組織患者中為29.6%,在HER2陽性和 RAS野生型血液檢測患者中為28.0%。

另外,作為Pertuzumab及Trastuzumab在HER2陽性大腸癌的輔助診斷劑,羅氏診斷公司的組織學檢查試劑盒Ventana ultraView Pathway HER2 (4B5)和雅培日本公司的 HER-2基因試劑盒Pathvision HER-2 DNA Probe Kit已獲批。

資料來源:https://www.chugai-pharm.co.jp/news/detail/20220328160000_1201.html

  • 臨床實驗用藥

   (肺癌)Topotecan及Topotecan+Berzosertib治療在第二期臨床試驗結果。   (肺癌)HER2基因變異非小細胞肺癌使用Trastuzumab deruxtecan有效?   (肺癌)抗B7-H3抗體藥物DS-7300有效?

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-984-3200
Formerly officially certified, No. B-066

圖片 1圖片 1

圖片 2圖片 2

圖片 3圖片 3

圖片 4圖片 4

相關癌症資訊

Related Reading